A newly engineered compound has shown promise in mice onboard the International Space Station (ISS) to prevent microgravity-induced bone loss. 

A multidisciplinary team of researchers from the University of California, Los Angeles (UCLA) and the Forsyth Institute in Cambridge, Massachusetts developed this novel molecule-based treatment. 

As per the official release, this could reduce the risk of  developing "extreme bone loss from long-duration space travel as well as musculoskeletal degeneration on Earth".

The scientists delved into the medicinal attributes of a protein referred to as 'NELL-like molecule-1 (NELL-1),' which holds a crucial function in the overall growth and upkeep of human bone structures.

To read more, click here.